Multi-Billion Biotech Acquisition
Merck secures exclusive rights to SciBrunch Therapeutics' cancer drug in a $2.13 billion deal.
Anonymous
Merck has secured exclusive worldwide rights to develop, manufacture and commercialize SciBrunch Therapeutics’ investigational oral drug SPR2015, a preclinical inhibitor targeting the cancer-associated KRAS G12D mutation. SciBrunch will receive $400 million upfront and could collect milestone payments that bring the agreement’s total value to $2.13 billion. Merck said the deal broadens its precision-oncology pipeline; the transaction has closed, and the company expects to record a $400 million pretax charge in the third quarter of 2026.
Key Points
1
Merck described SPR2015 as a potent, engineered KRAS G12D “ON” inhibitor. Merck executive George Addona said evidence is accumulating for targeting the KRAS pathway, a factor in tumor-cell growth.
2
SciBrunch said it is focused on RAS-pathway therapies for pancreatic, colorectal, lung and other major malignant tumors, and characterized the agreement as validation of its research-and-development platform.
3
The licensing deal complements Merck’s existing Keytruda franchise, according to GuruFocus, and could position the company in a market that includes cancers such as pancreatic and colorectal cancer.
4
Merck’s expected third-quarter charge is approximately 13 cents per share, in addition to the $400 million pretax amount.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
66
Reach
82
A
AnonymousAuthor
